Sera Prognostics Reports Strong Clinical Data but Faces Revenue Challenges
Event summary
- PRIME Study published in January 2026 shows PreTRM® Test reduces preterm births by 56% before 32 weeks and 32% before 35 weeks.
- Full-year 2025 revenue was $81,000, up slightly from $77,000 in 2024.
- Operating expenses held steady at $36.6 million for 2025, with net loss narrowing to $31.9 million from $32.9 million in 2024.
- Company raised $57.5 million in February 2025, extending cash runway through 2028.
The big picture
Sera Prognostics' landmark PRIME Study provides compelling evidence for the PreTRM® Test's ability to reduce preterm births, positioning it as a key player in maternal health diagnostics. The company is now focused on scaling commercial adoption, particularly in the U.S. and Europe, while managing its cash runway through 2028. Success will depend on securing payer coverage and demonstrating sustained revenue growth.
What we're watching
- Commercialization Pace
- Whether Sera can convert clinical validation into broader payer adoption and revenue growth.
- European Expansion
- The progress toward CE marking and regulatory approval in European markets.
- Leadership Impact
- How new executive appointments will drive commercial execution and market penetration.
Related topics